TABLE 3.

Susceptibility profiles of the PAO1 ampC knockout mutant PAΔC complemented with WT ampC and the ampC mutants identified in ceftolozane-tazobactam-resistant P. aeruginosa clinical isolates as described previously^a

Strain	MIC (mg/liter)b
	CAZ	CZA	TOL	C/T
PAO1	2	2/4	0.25	0.25/4
PAΔC	≤1	1/4	0.25	0.25/4
PAΔC/pUCPAmpCWT (PDC-1)	16	2/4	1	0.5/4
PAΔC/pUCPAmpCE247K (PDC-221)	>64	16/4	64	32/4
PAΔC/pUCPAmpCG183D (PDC-322)	32	16/4	16	8/4
PAΔC/pUCPAmpCT96I (PDC-222)	64	8/4	32	16/4
PAΔC/pUCPAmpCΔG229–E247 (PDC-223)	64	32/4	32	16/4

^aFraile-Ribot et al. (26) and MacVane et al. (27).

^bCAZ, ceftazidime; CZA, ceftazidime-avibactam; TOL, ceftolozane; C/T, ceftolozane-tazobactam.